Apogee Therapeutics presented positive Phase 2 results for its anti-IL-13 antibody APG777 in moderate-to-severe atopic dermatitis. The candidate demonstrated a 71% reduction in disease severity by week 16, outperforming existing therapies like Dupixent and Ebglyss, with the added benefit of potential quarterly or biannual dosing. Safety and secondary endpoints were favorable. Plans for Phase 3 studies and higher dose evaluations are underway, marking APG777 as a promising entrant in the eczema treatment market.